Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
• Males or females 18 years of age or older and 80 years of age or younger at the time of the first Screening Visit.
• ASA Classification 1 or 2.
• For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit.
• Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).
• Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.
• Positive for at least one clinical symptom consistent with SIBO.
• Positive lactulose breath test for SIBO, by Hydrogen (H2) criteria.
• Prescribed, but has not started, a two-week course of Rifaximin for SIBO.